Salvage chemoradiotherapy for locally advanced esophageal carcinomas.
'Salvage chemoradiotherapy (CRT)' was introduced in 2005 to treat thoracic esophageal carcinomas deemed unresectable based on the intraoperative findings. The therapeutic concept is as follows: the surgical plan is changed to an operation that aims to achieve curability by the subsequent definitive CRT. For this purpose, the invading tumor is resected as much as possible, and systematic lymph node dissection is performed except for in the area around the bilateral recurrent nerves. The definitive CRT should be started as soon as possible and should be performed as planned. We hypothesized that this treatment would be feasible and provide good clinical effects. We herein verified this hypothesis. Twenty-seven patients who received salvage CRT were enrolled in the study, and their clinical course, therapeutic response, and prognosis were evaluated. The patients who had poor oral intake because of esophageal stenosis were able to eat solid food soon after the operation. The radiation field could be narrowed after surgery, and this might have contributed to the high rate of finishing the definitive CRT as planned. As a result, the overall response rate was 74.1%, and 48.1% of the patients had a complete response. No patient experienced fistula formation. The 1-, 3-, and 5-year overall survival rates were 66.5%, 35.2%, and 35.2%, respectively. Salvage CRT had clinical benefits, such as the fact that patients became able to have oral intake, that fistula formation could be prevented, that the adverse events associated with the definitive CRT could be reduced, and that prognosis of the patients was satisfactory. Although the rate of recurrent nerve paralysis was relatively high even after the suspension of aggressive bilateral recurrent nerve lymph node dissection, and the rate of the progressive disease after the definitive CRT was high, salvage CRT appears to provide some advantages for the patients who would otherwise not have other treatment options following a non-curative and residual operation.
Department of Esophageal and General Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Y
Y
Nakajima
Department of Esophageal and General Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
K
K
Kawada
Department of Esophageal and General Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Y
Y
Tokairin
Department of Esophageal and General Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Y
Y
Miyawaki
Department of Esophageal and General Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
T
T
Okada
Department of Esophageal and General Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
T
T
Ryotokuji
Department of Esophageal and General Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
N
N
Fujiwara
Department of Esophageal and General Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
K
K
Saito
Department of Esophageal and General Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
H
H
Fujiwara
Department of Esophageal and General Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
T
T
Ogo
Department of Esophageal and General Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
M
M
Okuda
Department of Esophageal and General Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
K
K
Nagai
Department of Clinical Oncology, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
S
S
Miyake
Department of Esophageal and General Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
T
T
Kawano
D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy / Q000379:methods*; D018572:Disease-Free Survival; D004938:Esophageal Neoplasms / Q000473:pathology / Q000628:therapy*; D000077277:Esophageal Squamous Cell Carcinoma; D005260:Female; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D016879:Salvage Therapy / Q000379:methods*; D016896:Treatment Outcome
T4; esophageal carcinoma; multimodality treatment; non-curative surgery; salvage therapy